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forms of exit from work are included this figure rises to 617,764 YWLL (disability: 
121,323; unemployment: 106,502). A total number of 684,960 PYWLL were esti-
mated (401/1000) if early retirement is considered and 1,186,679 PYWLL (695/1000) 
for all forms of exit from work. The mean YWLL and PYWLL inactivity ratios were 
13% and 25%, respectively. ConClusions: We observed a high stock of accumu-
lated YWLL caused by RD in Portugal. Moreover, if nothing is done otherwise the 
amount of working life still to be lost from the current early retirees due to RD 
will almost equal those already gone, meaning that health policies should target 
not only job retention measures but also return-to-work ones.
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objeCtives: This study investigated the characteristics of the female osteoporosis 
population with increased fracture risk as defined by German guidelines and evalu-
ated the imminent (1-year) risk for fracture and the associated burden. Methods: 
This observational study used retrospective German sick fund data (~5% of the 
population). The sample was defined based on 2010 data while the study inves-
tigational year was 2011.Women with osteoporosis (WO) were considered to be 
at increased risk (IR) of fracture if they had at least one prescription for antire-
sorptive/anabolic drug, a history of osteoporotic fracture, or were identified with 
a condition or medication outlined in the German guideline. WO not meeting any 
of these criteria were considered “non-IR”. Descriptive analyses on osteoporosis 
related hospitalization, fracture frequency and osteoporosis related costs were per-
formed. Results: Among 74,974 WO, 39,969 (53.3%) were identified as being at IR. 
The mean age (SD) in the IR and non-IR group was 75.2 (9.5) and 74.0 (10.1) years, 
respectively. Approximately half of the IR patients received osteoporosis medica-
tion (43% bisphosphonate, 2.7% strontium, 0.9% denosumab, 1.5% raloxifen, 0.3% 
teriparatide). Estimated osteoporotic fracture occurrence was substantially higher 
in IR than in non-IR (9,647 vs 122 fracture events). IR patients were hospitalized at 
a higher rate compared to non-IR patients (14.8% vs 6.5%). Mean (SD) and median 
(IQR) annual osteoporosis-related costs (medication, hospitalization, outpatient 
treatment) were 1,405€ (3,193€ ) and 435€ (622€ ), respectively, for IR patients and 
640€ (2,110€ ) and 225€ (237€ ) for non-IR patients. ConClusions: Approximately 
half of the osteoporosis population met increased risk definition criteria. A note-
worthy proportion of these patients are at imminent risk for fracture based on the 
observed fracture events over a 12 months’ follow up. Despite being responsible for 
a disproportionately large disease burden and related health care costs less than 
half of the IR patients received medication for their osteoporosis.
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objeCtives: We aim to estimate indirect costs of early retirement caused by RD 
in Portugal. Methods: We used individual level data from the national, cross-
sectional, population-based EpiReumaPt study (Sep2011-Dec2013). 10,661 inhabit-
ants were randomly surveyed in order to capture and characterize all cases of RD 
within a representative sample of the Portuguese population. In this analysis we 
used all participants aged between 50 and 65 years old (yo), near the official retire-
ment age. An official national database was used to calculate productivity values 
by gender, age and region, using the human capital approach. All results were based 
on weighted data. Results: 29.9% of the Portuguese population with ages between 
50 and 64 yo were officially retired. Among these, 13.1% were retired due to RD. The 
estimated annual indirect cost following premature retirement caused by RD was 
€ 910 million (€ 555 per capita; € 1,625 per self-reported RD patient and € 13,592 per 
early retiree due to RD). Females contributed with 84% for these costs (€ 766 million; 
€ 882 per capita versus € 187 from males). The mean retirement age for early retirees 
due to RD was 54.8 yo. Thus, we estimate an average indirect cost of € 138,635 per 
early retiree due to RD until official retirement age (assuming 65 yo and fixed annual 
productivity values). Moreover, RD may underlie early retirement even when RD is 
not self-reported to be its cause, since we also found an independent association 
between all registered early retirement and self-reported RD (adjusted OR: 1.41; CI: 
1.03-1.95; p= 0.031), meaning that RD might further contribute for this sort of indirect 
costs. ConClusions: Early retirement caused by RD amounts to approximately 
0.5% of the national GDP 2013. The public health concern and the economic impact 
highlight the need to prioritize investments in health and social protection policies 
targeting patients with rheumatic conditions.
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objeCtives: To estimate annual health care resource utilization and direct medi-
cal cost for patients with osteoporotic fractures in Tianjin, China. Methods: Data 
were obtained from Tianjin Urban Employee Basic Medical Insurance database. 
Patients who ≥ 50 years old, with ≥ 1 diagnosed of osteoporotic fractures between 
2009 and 2010, and 12-month continuous enrollment before (baseline) and after 
(follow-up) the first observed osteoporotic fracture diagnosis were identified. Both 
osteoporosis-related and all-cause health care resource utilization and direct 
medical cost were estimated during the 12-month follow-up period. Ordinary 
least square regression model was applied to identify factors associated with 
the direct medical cost. Results: A total of 5941 patients were included, with 
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objeCtives: To investigate the cost per retention year for ustekinumab (UST) rela-
tive to infliximab (INF) in first line treatment of psoriatic arthritis (PsA) in Russian 
plaque psoriasis patients (PSO). Methods: A 10 year Markov model was con-
structed with UST and INF as first line biologic therapies and a two-step rescue 
therapy consisting of adalimumab (ADA) as the second line biologic for both treat-
ment arms and non-biologic supportive care of oral methotrexate 15mg/week (BSC) 
if the patient fails ADA. Transition probabilities were obtained from PSOLAR, an 
observational longitudinal study studying the safety of biologics in PSO and PsA, by 
fitting 5-year time-on-treatment data for self-identified PsA patients with confirmed 
PSO to a Weibull model and extrapolating over 10 years. All patients were assumed 
to have failed prior non-biologic therapy and retention on therapy was used as 
the target endpoint. Direct treatment costs were calculated from the perspective 
of the Russian Ministry of Health, converted to 2014 euros (1 RUB = € 0.0197) and 
discounted at 5%, as per Russian pharmacoeconomic guidelines. Results: Over a 
10 year horizon, INF-ADA-BSC was associated with a higher cost and a lower amount 
of retention years while the UST-ADA-BSC treatment line gives an additional 0.68 
biologic retention years per patient and a potential savings of € 29370 per patient 
with ustekinumab as first-line biologic treatment. However, these results were 
sensitive to changes in biologic drug prices and by extension, the market share of 
biosimilars. ConClusions: An increased retention time is usually correlated with 
higher patient satisfaction levels as well as response and safety. According to our 
model, initiating biologic therapy with ustekinumab is cost saving compared to the 
current first choice biologic, infliximab. However, further research has to be initiated 
to quantify the relationship between increased patient retention and additional gain 
in treatment response and safety.
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objeCtives: Ankylosing spondylitis (AS) is a form of spondyloarthritis with chronic 
inflammatory involvement of axial skeleton, variable peripheral joints and nonar-
ticular structures. The objective of this study was to determine the costs comparing 
patients under biologic therapy (BT) with those in conventional treatment (CT), 
under Brazilian private health care system’s perspective. Methods: We studied 6.5 
million members of a proprietary claim database, from January 2009 to December 
2012. Approximately 0.04% (2,626) was patients with ICD-10 AS-related. Most of them 
were from private health care plans. All medical out-patients and in-patients treat-
ment costs were studied, including drugs and ancillary diagnostic tests. Results: 
The females comprise 52% of this cohort, and 73.8% of them were between 18 and 
49 years old. Around 2,626 patients were treated, being 2,492 with CT and 134 with 
BT, primarily anti-TNF therapy.About 74% treated with CT presented any comor-
bidity, while 0.75% of those treated with BT. The total costs were USD3,668 for CT 
and USD4,575 for BT, with mean patient costs of USD1,980 for CT and USD4,575 for 
BT. The average hospitalizations costs for comorbidities were USD1,106, stressing 
that many of them were gastrointestinal complications of the disease. The average 
hospitalization costs under CT was USD7,988, considering under BT was USD1,271. 
The average days of hospitalization were 4.83 and 3.1 days for CT and BT, respec-
tively. The total costs of hospitalization of CT was USD511,217 being 62% due to 
materials (e.g., prosthesis) and USD25,428 for BT, being 17% due to materials and 
66% due to room rates and equipment rental. ConClusions: In this Brazilian pri-
vate claim database, BT had lower direct costs for hospitalizations and probability 
of comorbidities, when compared to CT. Although the mean patient cost with BT 
is higher than with CT, the lower probability of comorbidities occurrence with BT 
may justify its choice.
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objeCtives: The aim of this study was to calculate the years of working life lost 
(YWLL) caused by rheumatic diseases (RD). Methods: We used data from the 
cross-sectional, population-based EpiReumaPt study (Sep2011-Dec2013). 10,661 
inhabitants were randomly surveyed to capture all cases of RD within a represent-
ative sample of the Portuguese population. We analyzed participants aged between 
50 and 65 years old (yo), near the official retirement age. YWLL were determined 
for cases with premature retirement caused by RD (self-reported) estimated as 
the difference between each participant’s age and the respective retirement age 
(“observed stock”), while the potential YWLL (PYWLL: YWLL+“expected stock” of 
YWLL still to occur if there is no return-to-work) was the difference between 
official and actual retirement ages. We also calculated the percentage of time in 
inactivity (inactivity ratio = YWLL/Active age-range [15-65yo]). All results were 
based on weighted data. Results: 3.9% (n= 66,953/N= 1,706,750) of the Portuguese 
population (50-64 yo) had premature retirement caused by RD. The mean age of 
early retirement caused by RD was 54.8 yo, which led to a total stock of 389,939 
YWLL (228 per 1000 inhabitants). Women account for 85% of these YWLL. If all 
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economics and social security were extracted. The burden was measured for “LBP-
episodes”, defined as time periods with consecutive visits to the healthcare system 
with a relevant diagnosis code, continuing until 6 months have elapsed without 
costs incurred by LBP-related visits. Results: More than 72,000 patients were iden-
tified, with over 95,000 LBP-episodes. The average episode length was 56/176 days in 
episodes without/with surgery. The mean total cost per episode was estimated at 
€ 5,453, where indirect costs constituted 68.4%, medical visits including diagnostic 
imaging 14.5%, other inpatient care 8.2%, surgery 7.9%, and pharmaceuticals 1.0%. 
In men/women, the mean total cost per episode was estimated to € 22,174/€ 24,833 
in episodes with surgery, and € 4,175/€ 3,957 in episodes without surgery. The total 
burden of LBP in Sweden in 2012 was estimated at € 704M, with a burden per capita 
of € 73. Higher age, women, comorbidities, surgery and less education were found 
to be significant predictors of higher costs. ConClusions: The societal burden of 
LBP is substantial and varies significantly between different types of patients. It 
is important to identify periods and interventions within a LBP-episode that can 
be relevantly adjusted in order to optimize cost-effectiveness of treatment, and 
also, to realize that results may be dependent on the time frame chosen for a LBP-
episode. Acknowledgements: The study was financed with an unrestricted grant 
from Medtronic.
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objeCtives: The aim of this study was to calculate the years of working life lost 
(YWLL) from early exit from work associated with Osteoarthritis (OA). Methods: 
We used data from the population-based EpiReumaPt study (Sep2011-Dec2013). 
10,661 inhabitants were surveyed to capture all cases of RD within a representa-
tive sample of the Portuguese population. We analyzed all aged 50-65 years old 
(yo), near the official retirement age. YWLL were determined for OA cases with 
premature exit from work caused by RD (self-reported) estimated as the difference 
between each participant’s age and the respective age (“observed stock”), while the 
potential YWLL (PYWLL: YWLL+“expected stock” of YWLL still to occur if there is 
no return-to-work) was the difference between official and actual retirement ages. 
We also calculated the percentage of time in inactivity (inactivity ratio= YWLL/
Active age-range[15-65yo]). We excluded all OA participants with concomitant 
inflammatory rheumatic diseases with possible impact on retirement, such as 
rheumatoid arthritis and spondylarthritis. All cases with retirement prior to 
onset of OA symptoms were also excluded. All results were based on weighted 
data. Results: The estimated prevalence of OA in the Portuguese population 
(50-64 yo) is 29.7% (knee:18.6%; hand:12.6%; hip:3.6%). Among these, 61.8% were 
out of work versus 47.6% for those without OA (p= 0.004), which potentially led to 
162,735 YWLL (95 per 1000 inhabitants). Early retirement contributed the most for 
these YWLL (58%; 94,432 YWLL), followed by unemployment (35%; 57,209 YWLL) 
and disability pensions (7%; 11,094 YWLL). Women accounted for 80% of these 
YWLL (153 per 1000 female inhabitants). A total of 161,621 PYWLL were estimated 
if early retirement is considered and 369,839 PYWLL for all forms of exit from 
work. The mean YWLL and PYWLL inactivity ratios were 16% and 30%, respec-
tively. ConClusions: We estimated a considerable amount of working life years 
losses associated with OA in Portugal.
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objeCtives: To estimate the economic burden of hip fractures in Norway under 
different assumptions on the future demographic and fracture rate develop-
ment. Methods: Based on population projections from Statistics Norway and 
estimated fracture rates, we projected the future number of hip fractures in the 
period 2014-2040. We projected assuming both a low, medium and high population 
increase. We estimated fracture rates based on data from the hip fracture database 
of the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS), using data for 
the period 1999 to 2008. We predicted future fracture rates under three scenarios: 
assuming a constant future rate, assuming a continued decline in the fracture 
rate and assuming a continued, but somewhat reduced decline. We considered 
a medium population growth and a reduced decline as the most likely scenario. 
To the estimated number of fractures we added the cost of hip fracture surgery 
and other health and social care cost related to hip fractures from a recent Lancet 
publication. Results: The projected future cost in the period from 2014 to 2040 
varies from a 14% increase in the best-case scenario to 121% increase in cost in 
the worst-case scenario, with a 65% increase as the most likely estimate. From 
a hospital perspective, the costs could increase from € 108M to either € 119M in a 
best-case scenario or € 235M in a worst-case scenario. If we include not only the 
cost of the primary hospitalization, but also the cost of other health and social 
services (e.g. long term nuring home care) related to the fracture, the cost impact 
will increase from € 341M to € 388M either or € 766M ConClusions: Our study 
indicates that the number and cost of hip fractures is likely to increase until 2040, 
but the magnitude of the impact is very much dependent on demographic change 
and fracture rate development.
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mean age of 65.9 (±10.5) years, 62.1% female, and 88.2% retired. Annual mean 
all-cause cost was $2,466 per patient with osteoporosis-related cost accounting 
for 53.8%. For osteoporosis-related health services, 33.2% of patients experienced 
≥ 1 hospitalization with mean length of stay of 18.0 (±14.4) days and mean cost of 
$2,913 per admission, and 83.2% of patients experienced ≥ 1 outpatient visit with 
mean (±SD) number of visits 7.4 (±8.7) and mean cost $17 per visit. The medical 
device cost was the largest component (38.5%) of osteoporosis-related cost, fol-
lowed by drug cost (31.1%) and examination cost (11.7%). The regression model 
revealed that osteoporosis-related cost tended to increase with age, patients with 
hip, vertebral, lower leg and multiple fractures were more likely to have a higher 
cost. ConClusions: Costs for patients with osteoporotic fractures were consid-
erable in Tianjin China, driven mainly by osteoporosis-related hospitalizations. 
Efforts focused on reducing the utilization of inpatient services and increasing 
efforts to lower the fracture risks may have the potential to lighten the economic 
burden of osteoporotic fractures in China.
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objeCtives: The aim of this study was to assess the indirect costs caused by 
absenteeism associated with ankylosing spondylitis (AS) from the perspective of 
the Social Insurance Institution (ZUS) in Poland. Methods: The estimates were 
based on data from the year 2013 concerning absence from work due to the ill-
ness (sick leave) the amount of short-term disability, the sufferers of which claim 
rehabilitation benefit, and the amount of long-term disability (permanent or fixed 
time), the sufferers of which claim disability pension. Costs were calculated taking 
into account Gross Domestic Product (GDP) per capita equaled € 10 278, Gross Value 
Added (GVA) per worker equaled € 24 680 and Gross Income (GI) per worker equaled 
€ 7 339 were presented in 2013 prices. Results: Total indirect costs of AS in the year 
2013 calculated using GDP per capita, GVA and GI per worker in Poland were € 24 416 
394, € 58 631 008 and € 17 435 690, respectively. The highest component of indirect 
costs of AS was permanent long-term disability (68%). Sick leave and short-term 
disability costs constitute 12% and 4% of total indirect costs of AS, respectively. In 
2013 Poland’s Social Insurance Institution database reported 3 400 patients that 
had 7 137 sick leave episodes, 225 short-term disability episodes and 198 long-term 
disability episodes. Indirect costs per patient associated with sick leave were € 894, 
€ 2 147 and € 639 calculated using GDP, GVA and GI, respectively. Indirect costs per 
patient associated with short-term disability were € 259, € 622 and € 185 respectively 
and associated with long-term disability were as high as € 6 028, € 14 474 and € 4 304, 
respectively. ConClusions: AS in Poland generated high indirect costs. The main 
component was permanent long-term disability; short-term disability generated 
lower costs of lost productivity. The highest cost per patient was generated by per-
manent long-term disability.
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objeCtives: Chronic Inflammatory Rheumatic Diseases (CIRD), especially 
Rheumatoid Arthrits and Spondyloarthritis, are systemic inflammatory disorders 
significantly affecting patients’ quality of life. Disability and comorbidity associ-
ated to such conditions trigger high costs for healthcare systems and society. This 
analysis aims to measure direct costs in patients receiving pharmacological treat-
ment. Methods: Using administrative healthcare claims from the Piedmont region 
in the North-West of Italy, we detected CIRD patients who, during the period Jan 2008 
- Dec 2010, had > 1 disease-modifying antirheumatic drug (DMARD) prescription, 
either synthetic (e.g. methotrexate) or biologic (e.g. infliximab). RD was confirmed if 
patients had > 1 hospital diagnosis of CIRD (rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis, ICD-9 codes : 714.0, 696.0, 720.0) and/or an exemption code 
for similar diagnoses. Each patient was followed up from first DMARD prescription 
(index date) for three years or until death. Results: In the selected period N= 12,455 
patients with CIRD diagnosis received DMARD. Patients were mainly female (58.1%), 
with a mean age of 55.3 (+17.4) years. Direct annual costs were € 6,983, € 4,974, € 5,178, 
during Year 1, 2, 3. The composition of average annual costs was: € 1,531 (26.8%) 
for hospital costs and emergency room costs, € 163 (2.9%) for synthetic DMARDs, 
€ 2,188 (38.3%) for biologic DMARDs, € 985 (17.2%) for concomitant medications, € 845 
(14.8%) for ambulatory visits. N= 4,670 (37.5%) received biologic therapy during the 
follow-up. ConClusions: Chronic Inflammatory Rheumatic Diseases determine 
a relevant economic burden for healthcare services, because of significant epide-
miological impact and high per-patient costs. Costs are significantly high at every 
stage of disease, both at time of diagnosis, and over time.
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objeCtives: The objective of this study was to estimate the direct and indirect 
costs of low back pain with/without radiant pain (LBP) in Sweden using the concept 
of “LBP-episode”, and to identify the variation of these across different patients 
groups. Methods: Patients visiting healthcare providers, or receiving health insur-
ance benefits, with a LBP-diagnosis in the region of Västra Götaland in 2008-2012 
were identified in the administrative database VEGA. Data from additional Swedish 
national registers including inpatient and outpatient care, drug prescriptions, socio-
